Worth separating two things that the opening post runs together.
List prices versus negotiated prices: the price a pharmaceutical company publishes and the price an insurance company or pharmacy actually pays differ substantially. List price is not what anyone pays.
I would hold that lightly until someone with a larger sample weighs in.
Post #72 answers the question as asked. The question underneath it is different.
Where a price includes consultation, device and follow-up, saying so makes a comparison possible. Most quoted figures do not.
That has held every time I have looked, which is not the same as always.
A cheaper option that arrives slowly has a cost in the form of running out, and people rarely price that.
Two people in this thread mean different things by Price changes and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Taking post #122 at face value and following it one step further.
Comparing a licensed product's price to a research-use-only preparation's price is comparing two different things, and the difference is most of the explanation.
Read the full topic (157 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Pricing category
List prices, negotiated prices, and cost per milligram compared honestly across formats. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+1 | 5 | 18k | 15mo |
|
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. Working notes on List price versus negotiated price rather than a…
|
+24 | 28 | 50k | 12mo |
|
Cost per milligram, computed honestly across formats — the long version
Cost per milligram, computed honestly across formats — the long version Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because…
|
+111 | 124 | 24k | 14mo |
|
Cost per milligram, computed honestly across formats
Posting this under the heading it deserves: Cost per milligram, computed honestly across formats Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
2 | 47k | 18mo | |
|
Coming back to: Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here about cheapest…
|
+21 | 25 | 55k | 13mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Reading a denial letter as a specification for your appeal
Posting this under the heading it deserves: Revisiting: Reading a denial letter as a specification for your appeal Everything below is what sits behind that. Asking about Reading a denial letter on behalf of…
|
+125 | 138 | 9.4k | 10mo |
|
Peer-to-peer review: what actually happens on the call
On the subject in the title: Peer-to-peer review: what actually happens on the call Working notes rather than a conclusion. The question about peer-to-peer review that I actually want answered is the second…
|
2 | 1.2k | 1d | |
|
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…
|
+50 | 56 | 780 | 8mo |
|
Follow-up: Prior authorisation: what the criteria usually require
Prior authorisation: what the criteria usually require — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about Prior authorisation.…
|
+95 | 100 | 9.1k | 10h |
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. A methods question rather than a substantive one, about eu-wide position versus national…
|
2 | 54k | 19mo |